You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD34 stem cells

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Beta-Thalassemia, Thalassemia, Hematologic Diseases Trial (CTX001)

Not yet recruiting
  • Beta-Thalassemia
  • +6 more
  • CTX001
  • (no location specified)
Jul 26, 2022

Living Donor Kidney Transplantation Trial in Palo Alto, Chicago (Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs)

Recruiting
  • Living Donor Kidney Transplantation
  • Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
  • Palo Alto, California
  • +1 more
May 6, 2022

Fanconi Anemia Trial in Paris (G-CSF, Plerixafor)

Completed
  • Fanconi Anemia
  • Paris, France
    Hôpital necker-Enfants malades
Dec 20, 2021

Severe Combined Immunodeficiency Due to ADA Deficiency Trial in London (Infusion of autologous cryopreserved EFS-ADA LV CD34+

Active, not recruiting
  • Severe Combined Immunodeficiency Due to ADA Deficiency
  • Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)
  • +2 more
  • London, United Kingdom
    Great Ormond Street Hospital for Children NHS Foundation Trust
Dec 17, 2021

Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA), Severe Aplastic Anemia (SAA) Trial run by the NHLBI (Umbilical Cord

Completed
Has Results
  • Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)
  • Severe Aplastic Anemia (SAA)
  • Umbilical Cord Blood
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 16, 2021

Transfusion Dependent Beta-Thalassaemia Trial in Guangzhou, Shenzhen, Tianjin (ET-01)

Active, not recruiting
  • Transfusion Dependent Beta-Thalassaemia
  • ET-01
  • Guangzhou, Guangdong, China
  • +3 more
May 9, 2022

Beta-Thalassemia Trial in Worldwide (LentiGlobin BB305 Drug Product)

Active, not recruiting
  • Beta-Thalassemia
  • LentiGlobin BB305 Drug Product
  • Oakland, California
  • +8 more
Feb 4, 2022

Hematologic Diseases Trial in Kunming (BD211 Drug Product)

Enrolling by invitation
  • Hematologic Diseases
  • BD211 Drug Product
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Aug 14, 2021

Sickle Cell Disease Trial in United States (biological, drug, genetic)

Recruiting
  • Sickle Cell Disease
  • Plerixafor
  • +2 more
  • Oakland, California
  • +5 more
Sep 13, 2022

Adenosine Deaminase Deficiency, Severe Combined Immunodeficiencies (SCID) Trial in London (genetic, other, drug)

Completed
Has Results
  • Adenosine Deaminase Deficiency
  • Severe Combined Immunodeficiencies (SCID)
  • Infusion of autologous EFS-ADA LV CD34+ cells
  • +3 more
  • London, United Kingdom
    Great Ormond Street Hospital for Children NHS Foundation Trust
Aug 20, 2021

Mucopolysaccharidosis Type IIIA Trial in Manchester (Autologous CD34+ cells transduced with a lentiviral vector containing the

Active, not recruiting
  • Mucopolysaccharidosis Type IIIA
  • Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene
  • Manchester, United Kingdom
    Manchester University NHS Foundation Trust
Jul 2, 2021

Sickle Cell Disease Trial in Los Angeles, Boston (single infusion of autologous bone marrow derived CD34+ HSC cells transduced

Active, not recruiting
  • Sickle Cell Disease
  • single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
  • Los Angeles, California
  • +1 more
Feb 8, 2022

Lymphoma, Peripheral Blood Stem Cell Transplantation Trial (Eltrombopag olamine)

Not yet recruiting
  • Lymphoma
  • Peripheral Blood Stem Cell Transplantation
  • Eltrombopag olamine
  • (no location specified)
Jul 25, 2023

Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Worldwide (CTX001)

Active, not recruiting
  • Beta-Thalassemia
  • +4 more
  • CTX001
  • Stanford, California
  • +11 more
Nov 30, 2022

HIV Trial in United States (SB-728mR-HSPC Infusion 3 days following busulfan conditioning)

Active, not recruiting
  • HIV
  • SB-728mR-HSPC Infusion 3 days following busulfan conditioning
  • Duarte, California
  • +4 more
Mar 7, 2022

Hematologic Malignancies, Inborn Errors of Metabolism Disorders, Immune Deficiencies Trial in Durham (CliniMACS CD34 Reagent

Available
  • Hematologic Malignancies
  • +2 more
  • CliniMACS CD34 Reagent System
  • Durham, North Carolina
    Duke University Medical Center
Nov 12, 2021

Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease Trial in Pittsburgh (Cyclophosphamide, Mesna,

Recruiting
  • Systemic Sclerosis
  • +3 more
  • Pittsburgh, Pennsylvania
  • +2 more
Dec 17, 2021

MDS, Graft Vs Host Disease, Graft-versus-host-disease Trial in Miami (Busulfan, Melphalan, Fludarabine)

Not yet recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Miami, Florida
    Miami Cancer Institute
Jan 10, 2023

Mitochondrial Diseases, Pearson Syndrome Trial in Ramat Gan (MNV-201)

Recruiting
  • Mitochondrial Diseases
  • Pearson Syndrome
  • MNV-201
  • Ramat Gan, Israel
    Sheba Medical Center
Aug 24, 2023

Sickle Cell Disease Trial in Paris (DREPAGLOBE drug product)

Active, not recruiting
  • Sickle Cell Disease
  • DREPAGLOBE drug product
  • Paris, France
    Department of Biotherapy, Necker-Enfants Malades Hospital
Sep 26, 2022

Graft Vs Host Disease, Graft-versus-host-disease, Acute Myeloid Leukemia Trial (CliniMACS® device)

Not yet recruiting
  • Graft Vs Host Disease
  • +5 more
  • CliniMACS® device
  • (no location specified)
Jul 20, 2023

Mucopolysaccharidosis IH Trial in Milano (Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified

Active, not recruiting
  • Mucopolysaccharidosis IH
  • Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.
  • Milano, Italy
    Ospedale San Raffaele
Aug 6, 2021

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in New York (radiation, drug,

Completed
  • Acute Lymphoblastic Leukemia
  • +3 more
  • total body irradiation
  • +7 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 17, 2021

Hematologic Disorders Trial in Aurora (Miltenyi CliniMACS® CD34 Reagent System)

Recruiting
  • Hematologic Disorders
  • Miltenyi CliniMACS® CD34 Reagent System
  • Aurora, Colorado
    University of Colorado
Feb 22, 2022

Wiskott-Aldrich Syndrome Trial in Paris, London (Autologous CD34+ cells transduced with WASP lentiviral vector)

Active, not recruiting
  • Wiskott-Aldrich Syndrome
  • Autologous CD34+ cells transduced with WASP lentiviral vector
  • Paris, France
  • +1 more
May 31, 2021